Key result
Fosinopril administration was associated with significant decreases in urinary protein excretion, serum total cholesterol, and plasma lipoprotein(a) levels in patients with renal disease.
Why the study?
Does ACE inhibitor therapy improve proteinuria and lipid profiles, and what is the risk of hyperkalemia in patients with renal disease?
Does ACE inhibitor therapy improve proteinuria and lipid profiles, and what is the risk of hyperkalemia in patients with renal disease?
ACE inhibitors such as fosinopril may provide dual benefits in proteinuric renal disease by reducing both proteinuria and atherogenic lipids, though the risk of hyperkalemia requires consideration of tissue-specific ACE inhibition.
No takes yet. Share an insight, caveat, or question.
May support dual benefits on proteinuria and lipids in renal disease; leaves open confirmation in prospective trials.
Keilani et al. (1995) conducted a review in Renal disease. ACE inhibitors (fosinopril) was evaluated. Fosinopril administration was associated with significant decreases in urinary protein excretion, serum total cholesterol, and plasma lipoprotein(a) levels in patients with renal disease.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: